Celerion has been conducting clinical trials since its establishment in 1969, indicating over five decades of experience in early clinical research.
The facility in Lincoln, Nebraska, offers a large clinical capacity with approximately 600 clinic beds, allowing for the accommodation of numerous participants in various trials simultaneously.
Also worth reading: How does PCCT lung nodule AI integration improve diagnostic accuracy and workflow efficiency in modern radiology departments? · How does photon counting CT lung cancer screening compare to conventional CT for early detection and patient safety? · What are the definitive HSA vs FSA tax differences for 2026?
Celerion primarily focuses on Phase 1 clinical trials, which are crucial for determining the safety, dosage, and pharmacokinetics of new drugs in healthy volunteers.
The research conducted at Celerion helps pharmaceutical companies make early drug development decisions by providing essential insights into how medications are processed in the human body.
The Lincoln facility collaborates with both the University of Nebraska’s research community and private-sector businesses through partnerships established at the Nebraska Innovation Campus.
As part of its innovative approach, Celerion employs strategies like microtracer studies, which utilize small amounts of radioactive materials to track the absorption and distribution of drugs in the body.
High-throughput screening methods are employed to quickly evaluate the effects of potential drug candidates, contributing to faster decision-making in drug development.
Clinical trials at Celerion can involve studies on a range of medical conditions, with some trials specifically targeting healthy participants to gather baseline data.
The rigorous regulatory compliance in conducting clinical trials ensures that participants’ safety and wellbeing are prioritized throughout the research process.
Celerion utilizes a diverse workforce, comprising scientists, clinicians, and support staff, all of whom contribute expertise to various aspects of clinical research.
Participants in clinical trials are often compensated for their involvement, providing financial incentives for healthy volunteers to contribute to scientific research.
Data management and biometrics play critical roles in clinical trials, with advanced statistical analysis being employed to interpret study results accurately and effectively.
Most trials at Celerion utilize a randomized, double-blind study design, which minimizes bias and ensures that neither the participants nor the researchers know who receives the treatment versus a placebo.
Pharmacokinetics, the study of how drugs are absorbed, distributed, metabolized, and excreted by the body, is a key focus area in the trials conducted at Celerion, influencing decisions throughout the drug development process.
Celerion maintains partnerships with global pharmaceutical and biotech companies, enabling an exchange of knowledge that fosters innovation in early drug development.
Lincoln’s location allows for a stable cohort of participants, with many local residents choosing to engage in studies repeatedly due to their positive experiences.
Advanced technology, such as wearable devices for real-time health monitoring, is increasingly integrated into clinical research for improved data collection and participant tracking.
Celerion often implements adaptive trial designs, which allow for adjustments in the study protocol based on interim results, enhancing the trial's efficiency and effectiveness.
The ethical considerations involved in clinical trials are governed by Institutional Review Boards (IRBs), which ensure that research practices meet ethical standards and protect participants’ rights.
Clinical data from Celerion contributes not only to advancing individual drug development but also to the broader understanding of human health, providing insights that can lead to more effective treatments across a spectrum of diseases.